CITRYLL Trademark

Trademark Overview

On Thursday, July 3, 2025, a trademark application was filed for CITRYLL with the United States Patent and Trademark Office. The USPTO has given the CITRYLL trademark a serial number of 79433624. The federal status of this trademark filing is NON-FINAL ACTION COUNTED - NOT MAILED as of Friday, January 30, 2026. This trademark is owned by Citryll BV. The CITRYLL trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cancers, asthma, COPD, lupus, rheumatoid arthritis, vasculitis, idiopathic pulmonary fibrosis, lung disease, colitis, organ damage due to sepsis, atherosclerosis and cardiovascular disease; antibodies for the treatment of cancers, asthma, COPD, lupus, rheumatoid arthritis, vasculitis, idiopathic pulmonary fibrosis, lung disease, colitis, organ damage due to sepsis, atherosclerosis and cardiovascular disease; antibodies for the prevention or treatment of autoimmune diseases; small molecules and synthetic peptides for the prevention and treatment of cancers, asthma, COPD, lupus, rheumatoid arthritis, vasculitis, idiopathic pulmonary fibrosis, lung disease, colitis, organ damage due to sepsis, atherosclerosis and cardiovascular disease
citryll

General Information

Serial Number79433624
Word MarkCITRYLL
Filing DateThursday, July 3, 2025
Status640 - NON-FINAL ACTION COUNTED - NOT MAILED
Status DateFriday, January 30, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cancers, asthma, COPD, lupus, rheumatoid arthritis, vasculitis, idiopathic pulmonary fibrosis, lung disease, colitis, organ damage due to sepsis, atherosclerosis and cardiovascular disease; antibodies for the treatment of cancers, asthma, COPD, lupus, rheumatoid arthritis, vasculitis, idiopathic pulmonary fibrosis, lung disease, colitis, organ damage due to sepsis, atherosclerosis and cardiovascular disease; antibodies for the prevention or treatment of autoimmune diseases; small molecules and synthetic peptides for the prevention and treatment of cancers, asthma, COPD, lupus, rheumatoid arthritis, vasculitis, idiopathic pulmonary fibrosis, lung disease, colitis, organ damage due to sepsis, atherosclerosis and cardiovascular disease

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, October 23, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCitryll BV
Party Type10 - Original Applicant
Legal Entity Type98 - Unknown
AddressNL

Trademark Events

Event DateEvent Description
Thursday, October 2, 2025SN ASSIGNED FOR SECT 66A APPL FROM IB
Thursday, October 23, 2025LIMITATION FROM ORIGINAL APPLICATION ENTERED
Wednesday, January 28, 2026NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, January 28, 2026APPLICATION FILING RECEIPT MAILED
Thursday, January 29, 2026ASSIGNED TO EXAMINER
Friday, January 30, 2026NON-FINAL ACTION WRITTEN
Saturday, January 31, 2026NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

Related Keywords

citryll disease treatment organ colitis lung damage sepsis cardiovascular atherosclerosis pulmonary